Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NIH × Hepatitis C × navitoclax × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasm Metastasis 3 Small Cell Lung Carcinoma 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasms 1 Melanoma 1 Hepatitis C 1 Hepatitis B 1 Fibrosis 1 Carcinoma, Hepatocellular 1

Interventions

sofosbuvir-velpatasvir drug combination 1 rocakinogene sifuplasmid 1 navitoclax 1 Sorafenib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02143401 2024-11-22

Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed

Gastrointestinal

Fibrosis, Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡